Skip to main content

EDITORIAL article

Front. Microbiol., 05 September 2023
Sec. Infectious Agents and Disease
Volume 14 - 2023 | https://doi.org/10.3389/fmicb.2023.1281600
This article is part of the Research Topic Severe Fever with Thrombocytopenia Syndrome View all 5 articles

Editorial: Severe fever with thrombocytopenia syndrome

\r\nLi-Fen Hu,, Li-Fen Hu1,2,3*Yun-Jia Ning, Yun-Jia Ning4,5*Jia-Bin Li,, Jia-Bin Li1,2,3*
  • 1Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
  • 2Anhui Province Key Laboratory of Infectious Diseases, Anhui Medical University, Hefei, China
  • 3Institute of Bacterial Resistance, Anhui Medical University, Hefei, China
  • 4Wuhan Institute of Virology and Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China
  • 5Hubei Jiangxia Laboratory, Wuhan, China

Editorial on the Research Topic
Severe fever with thrombocytopenia syndrome

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by a novel bunyavirus, which was first isolated from China in 2010. This was an RNA virus belonging to Bunyavirales order, Pheniviridae family, Bandavirus genus which was renamed as Dabie bandavirus (DBV) by the International Committee on Taxonomy of Viruses in 2019. SFTS is increasingly becoming a public health threat due to its high morbidity and mortality. The DBV pathogenesis and severity of the disease are not yet clear. Besides, there are no specific treatment and preventive measures against DBV. More research should be focused on severe fever with thrombocytopenia syndrome.

The objective of this topic was to encourage original research about pathogenesis of multiple organ dysfunction syndromes and immune responses elicited by DBV, and secondary infection contribution to case fatality in SFTS patients such as bacterial and fungal infections, especially invasive pulmonary aspergillosis. After rigorous peer review, a total of four articles have been published in this Research Topic. Jin et al. mentioned that tripartite motif-containing 3 (TRIM3), as a member of the TRIM protein family can inhibit the production of cytokines by regulating the degradation of TLR3 through K48-linked ubiquitination, which can be a therapeutic target for improving the prognosis of SFTS. Dai et al. reported that smoking history, cough, creatinine, admission to ICU, broad-spectrum, and corticosteroid therapies were the independent risk factors for invasive pulmonary aspergillosis (IPA) in SFTS patients. There is a strong dose-dependent association between smoking and IPA development in SFTS patients. They emphasized that prophylactic antifungal therapy should be considered for SFTS patients with these risk factors. Chen et al. mentioned that Ferritin and PCT levels, especially ferritin, could be potential inflammatory biomarkers for predicting the prognosis of patients with SFTS in its early stages. Liang et al. showed a consistent rise in the incidence of SFTS over the past 12 years, accompanied by a relatively high case fatality rate, making it a critical public health issue. All the articles focused on the research about severity of the disease, which may be helpful for disease condition evaluation and treatment of SFTS patients.

Author contributions

L-FH, Y-JN, and J-BL wrote the original draft and reviewed and edited the Editorial. All authors contributed to the article and approved the submitted version.

Acknowledgments

The authors thank to the staff of the Frontiers team for the invitation to direct a new Research Topic in Frontiers in Microbiology section and for their kind assistance in conducting this work.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: severe fever with thrombocytopenia syndrome, antibody, invasive pulmonary aspergillosis, immunity, Dabie bandavirus

Citation: Hu L-F, Ning Y-J and Li J-B (2023) Editorial: Severe fever with thrombocytopenia syndrome. Front. Microbiol. 14:1281600. doi: 10.3389/fmicb.2023.1281600

Received: 22 August 2023; Accepted: 28 August 2023;
Published: 05 September 2023.

Edited and reviewed by: Axel Cloeckaert, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE), France

Copyright © 2023 Hu, Ning and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Li-Fen Hu, hulifen@ahmu.edu.cn; Yun-Jia Ning, nyj@wh.iov.cn; Jia-Bin Li, lijiabin@ahmu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.